NCT03504644 2026-02-25Venetoclax and Vincristine in Treating Patients With Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic LeukemiaEastern Cooperative Oncology GroupPhase 1/2 Active not recruiting40 enrolled 18 charts
NCT03808610 2026-01-09Low-Intensity Chemotherapy and Venetoclax in Treating Patients With Relapsed or Refractory B- or T-Cell Acute Lymphoblastic LeukemiaM.D. Anderson Cancer CenterPhase 1/2 Active not recruiting50 enrolled
NCT05565417 2025-10-16Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or LymphomasImmunitas TherapeuticsPhase 1/2 Active not recruiting67 enrolled
NCT03015896 2025-09-29Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin LymphomaOhio State University Comprehensive Cancer CenterPhase 1/2 Active not recruiting36 enrolled
NCT04404660 2025-09-09A Study of CD19 Targeted CAR T Cell Therapy in Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL)Autolus LimitedPhase 1/2 Active not recruiting153 enrolled 1 FDA
NCT02797470 2025-04-20Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell TransplantAIDS Malignancy ConsortiumPhase 1/2 Active not recruiting11 enrolled 9 charts